Loading company
$1.08-3.2%Nov 13 close
Next earnings: December 10, 2026
Figures through July 31, 2026, from the 10-K filed October 29, 2026
Past performance
- 1W
- +3.4%
- 1M
- -26.9%
- 3M
- -46.0%
- 6M
- -16.7%
- 1Y
- -11.9%
- 5Y
- -84.4%
$1.08-3.2%Nov 13 close
Next earnings: December 10, 2026
Figures through July 31, 2026, from the 10-K filed October 29, 2026
Rafael Holdings, Inc. is scheduled to report next on December 10, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending April 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toApr 30, 2026 | 3 months toApr 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $179K | $362K | -50.55% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“This submission is an important milestone for Rafael Holdings and, most importantly, for patients living with NPC,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is remibetadex (Trappsol® Cyclo™), for which we have completed a pivotal Phase 3 study in Niemann-Pick Disease Type C (“NPC”) and submitted an NDA to the FDA in October 2026. NPC is a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Rafael Holdings, Inc.’s Item 2.02 8-K filed October 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Rafael Holdings, Inc. has no earnings call transcript available.